Abstract: S200 Type: Oral Presentation Session title: Novel therapies and targets in MPN Background Polycythemia vera (PV) patients are treated with periodic therapeutic phlebotomy (TP) to maintain hematocrit levels . 45% in an effort to reduce the incidence of thrombotic events.. PV patients likely spend significant time with hematocrit levels >45%, between TP and …

EHA Travel GrantsThe call for travel grant applications will be open from January 1, 2025 until March 1, 2025 (23:59 CET).New: Grant applications have been integrated into the EHA2025 Abstract Submission form. Please indicate that you wish to apply for a ...

Bahar Uncu Ulu Ankara Oncology Training and Research Hospital Turkey

Abstract: EP791 Type: E-Poster Presentation Session title: Indolent and mantle-cell non-Hodgkin lymphoma - Clinical Background ZUMA-5 is a Phase 2 study of axi-cel anti-CD19 chimeric antigen receptor (CAR) T-cell therapy in patients with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL; follicular lymphoma [FL]; marginal zone lymphoma [MZL]).

2025年3月10日 · The European Health Data Space (EHDS) Regulation has made it to the EU’s Official Journal, almost three years after the initial proposal was published.. This crucial step in the EU’s digital health strategy is much-needed to improve access to and use of health data across the European Union, thereby enhancing diagnosis and treatments, and bolstering research …

Abstract: S210 Type: Oral Presentation Session title: Indolent & mantle cell lymphoma - Clinical Background Most patients with relapsed/refractory follicular lymphoma (r/r FL) experience multiple relapses and progressively worse clinical outcomes with each line of therapy, underlining a need for novel therapies. Tisagenlecleucel has demonstrated durable responses and manageable …

2025年3月10日 · A new clinical trial map was launched by EMA as part of the Clinical Trials Information System (CTIS) on March 3. The platform provides healthcare professionals and patients with easy, comprehensive, and real-time access to information about clinical tria...

Abstract: S213 Type: Oral Presentation Session title: Indolent & mantle cell lymphoma - Clinical Background Progression within 24 months from initiation of the first anti-CD20–containing chemoimmunotherapy (POD24) is an indicator of poor survival in indolent non-Hodgkin lymphoma (iNHL; Casulo & Barr.

A 10% discount on Air France or KLM airfares for EHA2025 attendees. Find out more. ITA Airways discount

June 5, 2025 EHA2025 Congress platform opens June 12-15, 2025 EHA2025 Milan, Italy - In-person and live stream Location Allianz MiCo, Milano Convention Centre August 15, 2025 EHA2025 Congress platform closes Scientific Program Committee ...